Laboratoires Théa

What Laboratoires Théa does

Laboratoires Théa is a privately-held, family-owned pharmaceutical company headquartered in Clermont-Ferrand, France, that is 100% dedicated to ophthalmology. Founded in 1989 by Henri Chibret and currently led by President Jean-Frédéric Chibret, the company develops, manufactures, and commercializes ophthalmic pharmaceutical products across ten therapeutic areas: ocular allergy, eyelid hygiene, dry eye, glaucoma, anesthesia, ocular infection, ocular inflammation, ocular herpes, mydriasis, and ocular nutrition. The portfolio is centered on preservative-free formulations and is positioned as 100% made in Europe.

The company's product technology comprises small-molecule ophthalmic therapeutics and targeted formulations (notably unit-dose, preservative-free presentations) developed through internal R&D and an "Open Innovation" platform that sources assets from biotech partners. Beyond its core portfolio, Théa has expanded its pipeline and reach through strategic collaborations: an exclusive license with LENZ Therapeutics for LNZ100 (an aceclidine-based presbyopia treatment) in Canada, and a strategic collaboration with Kiora Pharmaceuticals covering KIO-301 (retinitis pigmentosa) and KIO-104 (macular edema), with a $16 million upfront payment to Kiora recognized as 2024 revenue.

Commercially, Théa generates revenue primarily through prescription pharmaceutical sales of its branded ophthalmic products via direct owned subsidiaries in core markets (France, Germany, Italy, UK, USA, Austria, Belgium, Netherlands, Poland, Portugal, Romania, Greece, Ireland, Ukraine, Turkey, and the Nordics), supplemented by international distribution partners in markets such as Bulgaria, Switzerland, and Peru. A secondary revenue stream comes from licensing and milestone payments on partnered assets. Marketing is conducted through ophthalmology congresses (EMYO, ESCRS, AAO, EVER), the Théa Academy professional education platform, Fondation Théa, and a multilingual corporate website. The company employs between 1,001 and 5,000 people and serves patients and ophthalmology professionals across more than 30 countries.

Name

Laboratoires Théa

Legal name

Laboratoires Théa

Website

https://laboratoires-thea.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Laboratoires Théa is a privately-held French pharmaceutical company, headquartered in Clermont-Ferrand and 100% dedicated to ophthalmology. It develops, manufactures, and commercializes preservative-free prescription eye-care products across ten therapeutic areas in more than 30 countries via owned subsidiaries and distribution partners.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Ophthalmology Pharmaceuticals (HLAIAAAL)

akta.pro secondary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

Keywords

• Ophthalmic pharmaceuticals
• Eye care products
• Preservative-free formulations
• Glaucoma treatments
• Dry eye therapy

Headquarters

HQ city

Clermont-ferrand

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Sale of proprietary ophthalmic pharmaceutical products including treatments for glaucoma, dry eye, infections, inflammation, and other eye conditions. Revenue generated through direct sales in owned markets and through distributor networks.
2. Licensing and Milestone Payments: Théa receives upfront payments, regulatory milestones, and commercial milestones plus tiered royalties from licensing agreements such as the LNZ100 agreement with LENZ Therapeutics (over $70 million in potential milestones plus double-digit royalties).

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Laboratoires Théa is a European pharmaceutical company 100% dedicated to ophthalmology. It researches, develops, manufactures and commercializes a comprehensive portfolio of prescription eye care products across therapeutic areas including allergy, dry eye, glaucoma, ocular anesthesia, infections, inflammation, ocular herpes, mydriasis, eyelid hygiene, and ocular nutrition. The company emphasizes preservative-free formulations and 100% European manufacturing.

Product overview

Laboratoires Théa is a European pharmaceutical company exclusively dedicated to ophthalmology, offering a comprehensive portfolio of eye care products spanning multiple therapeutic domains. The company provides treatments across ten core areas: allergy, eyelid hygiene, dry eye, glaucoma, anesthesia, eye infections, inflammation, ocular herpes, mydriasis, and ocular nutrition. Théa maintains a commitment to preservative-free formulations and 100% European manufacturing. The company also expands its portfolio through strategic partnerships, including licensing agreements for innovative products like LNZ100 (aceclidine-based presbyopia treatment from LENZ Therapeutics for the Canadian market). Théa's operations extend across over 20 countries through affiliated offices in Europe, North America, and other international markets.

Differentiator

Problem solved

Functional benefit

Products and services

• Théa Allergy Treatments Therapeutic treatments for ocular allergies developed and commercialized by Laboratoires Théa as part of its ophthalmology portfolio for patients with allergic eye conditions.
• Théa Eyelid Hygiene Products Products for eyelid hygiene and management of eyelid pathologies as part of Théa's ocular health portfolio.
• Théa Dry Eye Treatments Therapeutic solutions for dry eye syndrome developed under Théa's commitment to preservative-free formulations.
• Théa Glaucoma Treatments Medications for glaucoma management forming a key part of Théa's ophthalmic therapeutic portfolio for intraocular pressure control.
• Théa Anesthesia Products Ophthalmic anesthesia solutions for surgical procedures in eye care.
• Théa Anti-Infective Products Treatments for ocular infections as part of Théa's comprehensive ophthalmology offerings.
• Théa Anti-Inflammatory Products Anti-inflammatory treatments for ocular inflammation developed by Laboratoires Théa.
• Théa Herpes Treatments Therapeutic treatments for ocular herpes (herpetic eye disease) in Théa's product portfolio.
• Théa Mydriasis Products Mydriatic agents for pupil dilation used in diagnostic and surgical ophthalmic procedures.
• Théa Ocular Nutrition Supplements Nutritional supplements designed to support ocular health and vision.
• LNZ100 An aceclidine-based eye drop candidate for treating presbyopia, licensed to Théa for exclusive registration and commercialization in Canada under a partnership with LENZ Therapeutics.

Quantifiable outcome

• Théa paid $16.0 million upfront to Kiora Pharmaceuticals for collaboration (recognized as revenue by Kiora in 2024)
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• LENZ TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 7 July 2025Exclusive license and commercialization agreement granting Théa rights to register and commercialize LNZ100, an aceclidine-based eye drop candidate for treating presbyopia, in Canada. Théa receives exclusive rights while LENZ Therapeutics is eligible to receive over $70 million in upfront, regulatory, and commercial milestone payments plus tiered double-digit royalties on net sales.
• Kiora PharmaceuticalscoreStrategic or Co-development PartnerStrategic collaboration involving a $16.0 million upfront payment from Théa to Kiora Pharmaceuticals, recognized as revenue by Kiora in 2024. The collaboration involves ongoing clinical developments and a strategic option agreement structure. Kiora is advancing KIO-301 (ABACUS-2 Phase 2 for retinitis pigmentosa) and KIO-104 (KLARITY Phase 2 for macular edema) in partnership discussions with Théa.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Direct peers

• Santen Pharmaceutical: Santen is a Japanese-headquartered, ophthalmology-focused pharmaceutical company with deep franchises in glaucoma, dry eye, and retinal disease. Closely mirrors Théa's pure-play, multi-therapeutic ophthalmic pharma model.
• Alcon: Alcon is the largest pure-play ophthalmology company globally, spanning surgical, vision care, and pharmaceutical products. Highly comparable to Théa across the pharmaceutical (drops, surgical pharma) business and the same ophthalmologist customer base.
• Bausch + Lomb: Bausch + Lomb (Bausch Health) operates a broad ophthalmology franchise covering pharmaceuticals, surgical devices, and consumer vision care. Direct competitor to Théa across ophthalmic drops and surgical pharmaceuticals, serving the same prescriber network.

Emerging players

• Kala Pharmaceuticals: Kala Pharmaceuticals focuses on novel ophthalmic therapies, particularly for dry eye and other front-of-eye conditions. Comparable to Théa in the dry-eye and ocular surface therapeutic areas but at an earlier commercialization stage.
• Ocular Therapeutix: Ocular Therapeutix is a US-based biopharm developing sustained-release ophthalmic therapeutics. Adjacent specialty-pharma model to Théa's, focused on ophthalmology but with a more pipeline-driven, single-asset concentration.
• Nicox: Nicox is a French ophthalmology R&D company developing therapeutics for glaucoma and ocular surface disease. Smaller and earlier-stage than Théa, but operates in the same French ophthalmology ecosystem and competes for the same prescriber mindshare.

Broad incumbents

• Allergan / AbbVie (Eye Care): AbbVie's Allergan Aesthetics/eye-care unit holds legacy ophthalmology assets (e.g., RESTASIS, OZURDEX) and competes across glaucoma, dry eye, and inflammation within a much larger diversified pharma portfolio. Larger and broader but overlaps heavily with Théa's core categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/LaboratoiresThea
• LinkedInlinkedin.com/company/laboratoiresthea

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries17 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laboratoires Théa